Navigation Links
Isolagen, Inc. Reports Receipt of Initiation of Delisting Proceedings Notice from Amex

Isolagen Intends to Appeal Action

EXTON, Pa., May 30 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (Amex: ILE) today announced that on May 29, 2008 it received notice from the staff of the American Stock Exchange (AMEX) indicating that, in the staff's opinion, the Company's plan of compliance did not demonstrate its ability to regain compliance with the Exchange's continued listing standards set forth in Sections 1003 (a)(i)-(iii) of the AMEX Company Guide within the prescribed time period, and, therefore, that its common stock is subject to being delisted from the Exchange. As discussed in the Company's Form 8-K dated March 14, 2008 and in Item 1A. of the Company's Form 10-Q for the quarter ended March 31, 2008, the Company had initially received a non-compliance notice from the staff of the AMEX on March 12, 2008, and had submitted a plan of compliance to the AMEX on April 14, 2008.

Isolagen intends to appeal this determination and will request a hearing before a committee of the Exchange. There can be no assurance that the Company's request for continued listing will be granted after such hearing.

About Isolagen, Inc.

Isolagen(TM), Inc. (Amex: ILE) is an aesthetic and therapeutic company committed to developing and commercializing scientific advances and innovative technologies. The company's technology platform includes the Isolagen Process(TM), a cell processing system for skin and tissue rejuvenation which is currently in clinical development for a broad range of aesthetic and therapeutic applications including wrinkles, acne scars, burns and periodontal disease. Isolagen also commercializes a scientifically-advanced line of skincare systems through its majority-owned subsidiary, Agera(R) Laboratories, Inc. For additional information, please visit

Isolagen Forward Looking Statements

All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release, include, without limitation, that the Company's request for continued listing with AMEX will be granted. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, as updated in "Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q filed since the annual report. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward- looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, as well as other public filings with the SEC since such date

SOURCE Isolagen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Isolagen, Inc. Sells Switzerland Facility
2. Isolagen, Inc. Promotes Todd Greenspan to Chief Financial Officer (CFO)
3. Isolagen, Inc. Receives Notification Letter from American Stock Exchange
4. Isolagen, Inc. Postpones Annual Meeting
5. Chem Rx Corporation Reports First Quarter 2008 Financial Results
6. CRH Medical reports Q1 2008 results
7. Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008
8. Unilens Vision Reports Increased Royalty Income
9. China Nepstar Chain Drugstore Reports Net Income Growth of 304.4% for First Quarter 2008
10. Shamir Optical Industry Ltd. Reports First Quarter 2008 Results
11. Nyer Medical Group, Inc. Reports Revenues of $18.9 Million With Net Loss of $.16 Per Share for 3rd Quarter of Fiscal Year 2008
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... Dr. Poneh Ghasri, dentist in West Hollywood ... 2015. The research, which was conducted at the Dental Institute at King's College London ... between stress during pregnancy and future dental health in the child. For years, researchers ...
(Date:10/13/2015)... ... October 13, 2015 , ... Leading ... Singal's newly launched "Publish Academy" training course . Singal's new program, in ... enrollment today, and marketers around the Internet are weighing in with reviews. , ...
(Date:10/13/2015)... ... October 13, 2015 , ... Scientists in Seattle and Vancouver compared the diagnostic ... or without mesothelioma. Surviving Mesothelioma has just posted an article on the new research. ... in Seattle and the University of British Columbia found that certain genetic alterations were ...
(Date:10/13/2015)... ... October 13, 2015 , ... California Southern ... Nursing. Dr. McLeod—who earned her Doctor of Nursing Practice from the renowned Johns ... spanned four decades. , Dr. McLeod’s long and successful nursing practice included a ...
(Date:10/13/2015)... ... October 13, 2015 , ... Breathing ... people do not breathe correctly. According to T’ai Chi (also spelled “Taiji”) and ... to breathe correctly, in concert with the 7,000 year old tradition they teach, ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... , Oct. 13, 2015  A minimally-invasive treatment just ... the United States.  After more than 10 years of ... 9 approved the use of High Intensity Focused Ultrasound ... cells while protecting surrounding tissue and minimizing chances for ... George Suarez , a pioneering Miami ...
(Date:10/13/2015)... , Oct. 13, 2015  ContraVir Pharmaceuticals, ... "Company"), a biopharmaceutical company focused on the development ... the closing of its previously announced underwritten public ... and warrants to purchase up to 3,000,000 shares ... combined price to the public of $3.00. The ...
(Date:10/13/2015)... -- Measurement in accountable care programs is essential for ... gaps in measurement can result in missed opportunities ... new, peer-reviewed study published in The ... measurement gaps for high-priority conditions and identifies ways ... --> "These gaps in measures present ...
Breaking Medicine Technology: